Persistent Peripheral Inflammation Attenuates Morphine-induced Periaqueductal Gray Glial Cell Activation and Analgesic Tolerance in the Male Rat

Lori N. Eidson
Anne Z. Murphy PhD
Georgia State University, amurphy@gsu.edu

Follow this and additional works at: https://scholarworks.gsu.edu/neurosci_facpub
Part of the Neuroscience and Neurobiology Commons

Recommended Citation
Persistent Peripheral Inflammation Attenuates Morphine-induced Periaqueductal Gray Glial Cell Activation and Analgesic Tolerance in the Male Rat

Lori N. Eidson and Anne Z. Murphy
Georgia State University
Neuroscience Institute

 Corresponding Author:
Anne Z. Murphy, Ph.D.
Neuroscience Institute
Georgia State University
100 Piedmont Ave
Atlanta GA 30303
Email: amurphy@gsu.edu
Phone: 404/413.5332
Fax: 404/413.5301

 Running Title: morphine induced tolerance and glia activation in PAG

 Key Words: opioids; tolerance; pain; inflammation; astrocytes; microglia
Abstract

Morphine is among the most prevalent analgesics prescribed for chronic pain. However, prolonged morphine treatment results in the development of analgesic tolerance. An abundance of evidence has accumulated indicating that CNS glial cell activity facilitates pain transmission and opposes morphine analgesia. While the midbrain ventrolateral periaqueductal gray (vIPAG) is an important neural substrate mediating pain modulation and the development of morphine tolerance, no studies have directly assessed the role of PAG-glia. Here we test the hypothesis that morphine-induced increases in vIPAG glial cell activity contribute to the development of morphine tolerance. As morphine is primarily consumed for the alleviation of severe pain, the influence of persistent inflammatory pain was also assessed. Administration of morphine, in the absence of persistent inflammatory pain, resulted in the rapid development of morphine tolerance and was accompanied by a significant increase in vIPAG glial activation. In contrast, persistent inflammatory hyperalgesia, induced by intraplantar administration of Complete Freund’s Adjuvant (CFA), significantly attenuated the development of morphine tolerance. No significant differences were noted in vIPAG glial cell activation for CFA-treated animals versus controls. These results indicate that vIPAG glia are modulated by a persistent pain state, and implicate vIPAG glial cells as possible regulators of morphine tolerance.

Perspective The development of morphine tolerance represents a significant impediment to its use in the management of chronic pain. We report that morphine tolerance is accompanied by increased glial cell activation within the vIPAG, and that the presence of a persistent pain state prevented vIPAG glial activation and attenuated morphine tolerance.
Introduction

Chronic pain, defined as pain lasting more than 3-6 months, will affect more than one in three Americans at some point in their life\textsuperscript{64, 66}. Although morphine is one of the most commonly prescribed analgesics\textsuperscript{76}, secondary side effects (e.g., tolerance) limit its efficacy for long-term chronic pain treatment\textsuperscript{8, 28, 48, 49}. In the absence of pain, morphine tolerance, defined as the requirement for steadily larger doses of opioids to achieve the same analgesic effect, develops quite rapidly\textsuperscript{19, 48, 54}. In contrast, clinical studies have consistently reported that the latency to develop morphine tolerance is increased in chronic pain sufferers, although dose escalation is eventually required for the maintenance of analgesic efficacy\textsuperscript{77}. Dose escalation leads to increased risk of developing additional negative side effects, including anti-analgesia, addiction, withdrawal, and respiratory depression\textsuperscript{76}, and is not always sufficient to overcome tolerance and reinstate analgesic efficacy\textsuperscript{77}. As over 90% of chronic pain sufferers are treated with opioids\textsuperscript{76}, including morphine, elucidation of the mechanisms by which morphine tolerance develops warrants investigation.

The midbrain ventrolateral periaqueductal gray (vlPAG) and its descending projections to the rostral ventromedial medulla (RVM) and spinal cord, comprises an important neural circuit for both endogenous and exogenous opioid-mediated analgesia\textsuperscript{4-7, 24}. In rats, chronic subcutaneous injections of morphine result in tolerance to subsequent doses of morphine, an effect that is eliminated by intra-vlPAG injections of the opioid receptor antagonist naltrexone\textsuperscript{42}. In addition, chronic intra-vlPAG injections of morphine induce tolerance, and this effect remains when the RVM, the primary downstream target of the PAG, is inhibited with the GABA agonist muscimol\textsuperscript{42}. 
An abundance of evidence has accumulated indicating that systemic morphine administration activates glial cells, including microglia and astrocytes\textsuperscript{31, 51, 52, 60, 70, 75, 84}. Song and Zhou (2001) reported that chronic morphine administration results in the activation of astrocytes within the cingulate cortex, hippocampus and spinal cord, and that blockade of glial activation within the spinal cord attenuates the development of morphine tolerance. Since then, a myriad of studies have been published implicating glia activation in the development of morphine tolerance\textsuperscript{84, 85} and pain facilitation\textsuperscript{11, 61, 82}. While it is clear that the activation of microglia and astrocytes contribute to the development of morphine tolerance, no studies have examined the role of activated glia within the PAG, a primary site of morphine action. Similarly, the influence of a persistent inflammatory pain state on PAG glial cell activation has not been assessed. The present study tested the hypothesis that morphine-induced increases in vlPAG glial cell activity contribute to the development of morphine tolerance, and that persistent inflammatory pain alters this activation, resulting in the attenuation of morphine tolerance.

**Materials and Methods**

**Subjects**

Weight-matched (250-350g) male Sprague Dawley rats (Charles River, Wilmington, MA) were pair-housed on a 12:12 hour light: dark cycle. Access to food and water was available *ad libitum* throughout the experiments except during behavioral testing. All studies were approved by the Institutional Animal Care and Use Committee (IACUC) at Georgia State University, and performed in strict compliance with Ethical Issues of the International Association for the Study of Pain (IASP) and National Institute of Health (NIH). All efforts were made to reduce the
number of animals used in these experiments and to minimize any possible suffering by the animal.

**Persistent Inflammatory Hyperalgesia**

In a subset of animals, persistent inflammatory hyperalgesia was induced by injection of complete Freund’s adjuvant (CFA; Mycobacterium tuberculosis; Sigma; 200 µl), suspended in an oil/saline (1:1) emulsion, into the plantar surface of the right hindpaw as previously described\(^46,\ 48,\ 81\). As intraplantar saline administration results in a short-term inflammatory response, control animals were restrained in a similar manner but did not receive an intraplantar injection.

**Experiment 1: Influence of Persistent Inflammatory Pain on Morphine Tolerance**

Twenty-four hours following intraplantar CFA injection or handling, animals were administered morphine (5 mg/kg, sc; NIDA) or saline (1 ml/kg, sc) once a day for three consecutive days (CFA+Morphine; CFA+Saline; Handled+Morphine; Handled+Saline). The 5 mg/kg dose was chosen based on our previous studies demonstrating this to be the 50% effective dose (ED\(_{50}\)) for systemic morphine in male rats\(^47,\ 53,\ 81\). Baseline nociceptive thresholds were measured before morphine or saline injections, and 15 minutes following the first and last injection (Injection 1 and Injection 3, respectively). Tolerance was assessed on Day 5 (Day 1 being CFA administration), by injecting cumulative doses of morphine every 20 min, resulting in doses of 3.2, 5.6, 8.0, 10.0 and 18.0 mg/kg as previously described\(^48\). Nociception was assessed using the paw thermal stimulator\(^29\) 15 min after each injection\(^81\). Briefly, for this test, the rat is placed in a clear Plexiglas box resting on an elevated glass plate maintained at 30°C. A radiant beam of light is positioned under the hindpaw and the time for the rat to remove the paw from
the thermal stimulus is electronically recorded as the paw withdrawal latency (PWL). The intensity of the beam was set to produce basal withdrawal rates of 7-9 seconds. A maximal PWL of 20.48 seconds was used to prevent excess tissue damage due to repeated application of the noxious thermal stimulus. Animals were acclimated to the testing apparatus (30 minutes a day for 3 consecutive days) at the start of the experiment. All behavioral testing took place between 12:00pm and 5:00pm (lights on at 7:00am). All testing was conducted blind with respect to group assignment (i.e., morphine or saline treatment).

Behavioral data analysis and presentation

Behavioral data are expressed in raw seconds. Paw withdrawal latency data were analyzed using repeated measures ANOVA for significant main effect of pain (CFA or handled) and treatment (morphine or saline) across dose. Pre-planned t-tests were used to determine specific group and dose differences when a significant main effect was observed. All values are reported as Mean ± S.E.M.; p < 0.05 was considered statistically significant.

**Experiment 2: Anatomical Assessment of Morphine Tolerance**

Twenty-four hours following intraplantar CFA or handling, animals were administered morphine (5 mg/kg; sc) or saline (1 ml/kg; sc) once a day for three consecutive days as described above (CFA+Morphine, CFA+Saline, Handled+Morphine, Handled+Saline). One hour following the last injection of morphine or saline, animals were given a lethal dose of Nembutal (160 mg/kg; i.p.) and transcardially perfused with 250 ml of 0.9% sodium chloride containing 2% sodium nitrite as a vasodilator to remove blood from the brain. Immediately following blood removal, 300 ml of 4% paraformaldehyde in 0.1M phosphate buffer containing 2.5% acrolein (Polysciences Inc.; Warrington, PA) was perfused through the brain as a fixative. A final rinse with 250 ml of
sodium chloride/sodium nitrite solution was perfused through the brain to remove any residual acrolein. Brains were removed and placed in a 30% sucrose solution and stored at 4°C until sectioning. To examine the acute effects of morphine on vIPAG glia activation, a separate group of animals received one sc injection of morphine (or saline) and were sacrificed 1 or 24 hours later. A separate group of animals (CFA+Morphine, CFA+Saline, Handled+Morphine, Handled+Saline) were decapitated immediately following treatment for western blot analysis. Brains were removed, flash frozen in 2-methyl-butane on dry ice, and stored at -80°C.

**Immunohistochemistry**

Hallmarks of glial cell activity include increased cytokine release that correlates with increased expression of the protein markers glial fibrillary acetic protein (GFAP; astrocytes), and CD-11b (OX-42; microglia)\(^6^0\). Further, increased glial cell activity is evidenced by a profound shift in morphology that can be easily visualized using immunohistochemistry for GFAP and OX-42\(^1^6\). Perfused brains were sectioned into 25µm coronal sections with a Leica 2000R freezing microtome and stored free-floating in cryoprotectant-antifreeze solution\(^4^4\) at -20°C. A 1:6 series through the rostrocaudal axis of each brain was processed for GFAP and OX-42 immunoreactivity using standard immunohistochemical techniques\(^5^6\). Briefly, sections were rinsed extensively in potassium phosphate-buffered saline (KPBS) immediately followed by a 20-minute incubation in 1% sodium borohydride. The tissue was then incubated in primary antibody solution (rabbit anti-GFAP 1:5,000 or rabbit anti-OX42 1:1000; Abcam) in KPBS containing 1.0% Triton-X for one hour at room temperature followed by 48 hours at 4°C. After rinsing with KPBS, the tissue was incubated for one hour in secondary antibody (biotinylated IgG goat anti-rabbit 1:600), rinsed with KPBS, and then incubated for one hour in an avidin-
biotin peroxidase complex (1:10; ABC Elite Kit, Vector Labs). After rinsing in KPBS and sodium acetate (0.175 M; pH 6.5), GFAP or OX-42 immunoreactivity was visualized as a black reaction product using nickel sulfate intensified 3,3’-diaminobenzidine (DAB) solution (2 mg/10ml) containing 0.08% hydrogen peroxide in sodium acetate buffer. After 15 minutes, tissue was rinsed in sodium acetate buffer followed by KPBS. In a subset of sections, GFAP (Rabbit anti-GFAP 1:3,000; Abcam) or OX-42 (Mouse anti-CD11b 1:3000; Serotec) was visualized using a fluorescent secondary antibody (goat anti-rabbit Dylight488 1:50 for GFAP and rabbit anti-mouse Cy3 1:50 for CD11b; Jackson Immunoresearch Laboratories). Following secondary incubation, sections were rinsed in KPBS. DAB and fluorescent sections were mounted out of KPBS onto gelatin-subbed slides, air-dried and dehydrated in a series of graded alcohols. Tissue-mounted slides were then cleared in Xylenes and glass cover-slipped using Permount for DAB reactions or Krystalon for fluorescence.

**Western blotting**

Flash frozen brains were sectioned at 300µm on a cryostat (Leica, Buffalo Grove, IL) and mounted onto slides. One-millimeter bilateral micropunches were taken from 6 levels for the vlPAG (Bregma -8.52, -8.28, -7.92, -7.68, -7.20, and -6.96) and 6 levels of the superior colliculus (Bregma -7.68, -7.20, -6.96, -6.60, -6.24, and -5.80), and homogenized in a 10mM HEPES buffer (pH 7.2). Equal amounts of protein (2µg) along with a standard marker (Bio-Rad, Hercules, CA) were run at 100V for 2 hours through 10% Tris-HCl polyacrylamide gels (Bio-Rad, Hercules, CA), and electro-transferred at 4°C on ice at 250mA for 2 hours onto PVDF membranes (0.2µm pore size; Bio-Rad, Hercules, CA). Membranes were blocked with 5% milk in TBS-Tween 20 (1%) at 4°C overnight, and probed with rabbit anti-GFAP primary antibody
(1:300,000; Abcam) in 2% milk/TBS-Tween 20 (1%) for 3 hours at room temperature followed by a 30 minute incubation in HRP-conjugated goat anti-rabbit secondary (1:5000; Abcam) in 2% milk/TBS-Tween 20 (1%). Rabbit anti-β-actin primary (1:10,000; Novus Biologicals) was included as a control for protein loading. Membranes were stripped and reprobed with mouse anti-rat CD11b (OX-42, 1:700; Serotec) followed by HRP-conjugated goat anti-mouse (OX-42; 1:5000; Abcam) and HRP-conjugated goat anti-rabbit (β-actin; 1:5000; Abcam) secondaries.

Anatomical data analysis and presentation

Levels of GFAP and OX-42 immunoreactivity in the vlPAG were compared across treatment groups using semi-quantitative densitometry as previously described\textsuperscript{43,48}. To determine if the observed changes in glia activation were limited to the vlPAG, sections through the superior colliculus (SC), a region containing a high density of μ opioid receptors (MOR) but not implicated in opioid modulation of pain, were also analyzed. 12-bit grayscale images that included the region of interest (ROI) were captured using a QImaging Retiga EXi CCD camera (Surrey, BC, Canada) and iVision Image analysis software (Biovision Technologies, Exton, PA). Grayscale values for each image were inverted so that higher values were representative of increased staining levels. Images of three slices through each ROI for each animal were analyzed and data sampled unilaterally. Data sampling occurred by using the drawing tools in iVision to outline the ROI and using the “measure” function to determine an average grayscale pixel value for the outlined area. ROI measures were corrected for nonspecific binding by subtraction of background measure taken from gray matter adjacent to the ROI. Data were analyzed across 3 representative levels through the rostral-caudal axis of the vlPAG (Bregma -7.08, -7.68, and -8.30)\textsuperscript{58} and superior colliculus (Bregma -7.68, -6.24, and -5.80)\textsuperscript{58} as previously
described\textsuperscript{48}. Densitometry values are presented as the mean ± S.E.M. density of immunoreactivity. Data were analyzed using an ANOVA to determine significant main effects of treatment (morphine, saline) and pain (CFA, handled). Fisher’s post hoc tests were used to determine specific group differences when a significant main effect was observed; \( p \leq 0.05 \) was considered statistically significant. For Western blots, band intensities for tissue from the vlPAG and superior colliculus were visualized at 55kD (GFAP) and 160kD (CD11b), and quantified using ImageJ (NIH, USA) analysis software, as a relative intensity of GFAP or CD11b band divided by the intensity of the \( \beta \)-actin band. Data are expressed as the mean ratio ± S.E.M of protein of interest/\( \beta \)-actin. Data were analyzed for significant main effects of treatment (morphine, saline) and pain (CFA, handled) using an ANOVA, and Fisher’s HSD was used for post-hoc analysis; \( p \leq 0.05 \) was considered statistically significant.

Results

**Experiment 1: Persistent Peripheral Inflammation Attenuated Morphine Tolerance**

To assess the initial analgesic potency of morphine, and the degree and time course for development of morphine tolerance, paw withdrawal latencies (PWL) were determined for both the injured (ipsilateral; right) and uninjured (contralateral; left) hindpaws at baseline, and after Day 1 and Day 3 of morphine or saline. Contralateral (uninjured) PWL did not differ between CFA+Saline and Handled+Saline groups at any time point (Figure 1A). By contrast, intraplantar CFA significantly decreased ipsilateral PWL 24, 48, and 96 hours post injection as compared with handled controls (CFA+Saline versus Handled+Saline; Figure 1B) indicating the development of persistent hyperalgesia. Administration of morphine on Day 1 and 3 significantly increased both contralateral and ipsilateral PWLs as compared with saline controls.
(Figure 1A and B, respectively). For the contralateral paw, administration of morphine (Day 1) produced comparable levels of analgesia in the CFA+Morphine and Handled+Morphine groups (Figure 1A). However, the degree of analgesia produced by morphine on Day 3 was significantly attenuated in the Handled+Morphine vs. the CFA+Morphine animals, suggesting the development of morphine tolerance (Figure 1A). In the ipsilateral hindpaw, administration of morphine on Day 1 produced anti-hyperalgesia in CFA treated animals as indicated by a return to normal baseline PWL (CFA+Morphine; Handled+Saline, Figure 1B). In contrast to the decreased analgesia observed in Handled+Morphine animals on Day 3, morphine produced a significant increase in ipsilateral PWL of injured animals on Day 3 as compared to Day 1 (CFA+Morphine; Injection 1 and Injection 3, Figure 1B) indicating lack of tolerance development.

Assessment of morphine tolerance

Morphine tolerance, assessed on Day 5 using a cumulative dosing paradigm, was only observed in non-CFA treated animals. As shown in Figure 2, the antinociceptive potency of morphine was significantly decreased in both the ipsilateral and contralateral hindpaw of uninjured animals that received 3 consecutive days of morphine (Handled+Morphine) as compared with uninjured animals that received saline (Handled+Saline; Figures 2A and C). Indeed, animals that received 3 days of saline reached 100% maximum possible analgesia (MPE) at the 8 mg/kg dose. In contrast, 100% MPE was not noted until the 18 mg/kg dose in animals that received 3 prior days of morphine. Neither the antinociceptive nor the antihyperalgesic potency of morphine was different in CFA+Morphine treated animals as compared with CFA+Saline treated animals (Figures 2B and D) indicating lack of tolerance development. Indeed, no differences in PWLs
produced by morphine were noted for all doses tested. Together these data indicate that persistent inflammatory pain attenuates the development of tolerance to morphine.

As glia activation in the spinal cord has been implicated in the development of morphine tolerance, the next series of experiments examined if glia were similarly activated within the vIPAG, and if persistent inflammatory pain altered their activation.

**Experiment 2: Morphine Tolerance is Associated with Increased Glial Cell Activation in the vIPAG**

Increased activity of astrocytes, as evidenced by an increase in GFAP immunoreactivity, was only observed in non-CFA treated animals that received morphine (Handled +Morphine, Figure 3B). A representative example of vIPAG GFAP staining in animals administered CFA+Morphine versus Handled+Morphine is shown in Figure 3A. Western blots confirmed increased activity of astrocytes, as evidenced by an increase in relative band intensity of GFAP/ β-actin, was only observed in non-injured animals that received morphine (Handled+Morphine, Figure 3C).

Similar to what was noted for astrocytes, microglia activity, as evidenced by OX-42 immunoreactivity, was significantly increased in animals that received morphine in the absence of pain (Handled+Morphine, Figure 4B). A representative example of vIPAG OX-42 staining in animals administered CFA+Morphine versus Handled+Morphine is shown in Figure 4A. A trend towards increased activity of microglia, as evidenced by an increase in relative band intensity of OX-42/β-actin, was only observed in animals that received morphine in the absence of pain (Handled+Morphine, Figure 4C); however, it did not reach statistical significance. Peripheral inflammation induced by intraplantar CFA did not illicit significant increases in vIPAG glial cell activity (Figures 3 and 4). Importantly, one injection of morphine (5 mg/kg) was not sufficient to
alter vlPAG GFAP (Figure 5A) or OX-42 levels (Figure 5B) at 24 hours post-morphine. Similarly, no increase in GFAP or OX-42 levels were noted 1 hour post-morphine (data not shown). No significant group differences were noted in superior colliculus GFAP or OX-42 immunoreactivity ($F_{3,23}=2.089$, $p=0.1295$ and $F_{3,19}=1.416$, $p=0.2690$, respectively) or protein level ($F_{3,28}=0.232$, $p=0.8730$ and $F_{3,6}=1.822$, $p=0.2435$, respectively), indicating that changes in vlPAG glial cell activity are region specific (data not shown).

**Discussion**

The present experiments tested the hypothesis that vlPAG glial cell activity contributes to the development of morphine tolerance. Clinical studies indicate that chronic pain attenuates the development of morphine tolerance$^{37, 77}$; however, animal studies have yielded variable results$^{35, 65, 78}$. Therefore, the impact of persistent inflammatory hyperalgesia on morphine tolerance development and glial activation were also investigated. Here we report that (1) short-term daily administration of an ED50 dose of morphine was sufficient to induce morphine tolerance; (2) persistent inflammatory pain induced by intraplantar CFA significantly attenuated morphine tolerance; and (3) increased vlPAG microglia and astrocyte activity was only observed in those animals made tolerant to morphine. Together, these data suggest a potential role for vlPAG microglia and astrocytes in the development of morphine tolerance, and suggest that persistent inflammatory pain attenuates morphine tolerance by inhibiting morphine-induced vlPAG glial cell activation.

*Increases in vlPAG microglia and astrocyte activity correlate with the development of morphine tolerance*
Many mechanisms have been proposed to account for opioid tolerance, including decoupling, internalization and/or down-regulation of μ opioid receptors\textsuperscript{67, 68}, upregulation of NMDA receptor function\textsuperscript{1-3}, down-regulation of glutamate transporters\textsuperscript{9, 59}, and production of nitric oxide (a known mediator of NMDAR function)\textsuperscript{84}. These mechanisms were all thought to implicate some form of ‘neuronal adaptation’\textsuperscript{84}. However, it is becoming increasingly clear that activated glia mediate many of these ‘neuronal adaptations’ that contribute to morphine tolerance\textsuperscript{84}. Consistent with previous reports, here we find that tolerance to morphine developed rapidly in the absence of pain\textsuperscript{41, 42, 48}. Indeed, one ED\textsubscript{50} dose of morphine (5 mg/kg) injected subcutaneously for three days was sufficient to induce behaviorally defined tolerance. Paralleling the development of tolerance, GFAP and OX-42 protein levels increased significantly within the vlPAG, suggesting the activation of astrocytes and microglia, respectively.

A large body of evidence has accumulated implicating opioids as activators of spinal astrocytes and microglia\textsuperscript{31, 60, 63, 86}. In both mice and rats, morphine increases spinal GFAP and OX-42 protein levels,\textsuperscript{20, 33} as well as glially derived proinflammatory cytokines\textsuperscript{32, 63}. Inhibition of spinal glia or cytokine release increases the analgesic efficacy of morphine\textsuperscript{32, 63}, and attenuates morphine tolerance\textsuperscript{31, 51, 52, 60, 70}. Our novel findings in the vlPAG parallel the data from studies of spinal cord glia, and indicate that supraspinal glial cell activity may also contribute to the development of morphine tolerance.

Under basal conditions glia survey the environment for pathogens, debris, and regulate ion and neurotransmitter levels in the synapse to modulate neuronal excitability\textsuperscript{86}. The activation of glia results in the release of excitatory substances that oppose morphine analgesia (e.g., proinflammatory cytokines)\textsuperscript{86}. Glial release of cytokines increases with chronicity of morphine
administration, making these excitatory substances key players in the development of morphine tolerance. Glially-derived cytokine release, particularly tumor necrosis factor alpha (TNFα) and interleukin-1 beta (IL-1β), results in increased density and conductance of neuronal AMPA71 and NMDA receptors, decreased astrocytic glutamate transporter proteins (GLT-1, GLAST)86, and down-regulation of neuronal GABA receptors71. These cytokine-induced changes, among others39,55, effectively increase neuronal excitability. Morphine binds to neuronal μ opioid receptors (MOR) in the vlPAG that are primarily located on GABAergic neurons14,18,38; MOR binding in the vlPAG disinhibits GABAergic PAG-RVM projection neurons25, resulting in the net excitation of the PAG-RVM-spinal cord descending pain modulatory circuit. Glial-induced increases in the excitability of vlPAG MOR-containing neurons may act to alter the inhibitory properties of morphine, thereby decreasing analgesic efficacy and contributing to the development of morphine tolerance.

**Persistent inflammatory pain prevented morphine-induced increases in vlPAG glial cell activity and attenuated the development of morphine tolerance**

The results of the present study demonstrate that the presence of persistent pain alters both the development of morphine tolerance and morphine-induced vlPAG glial cell activation. The finding that persistent peripheral inflammation attenuates morphine tolerance is consistent with the clinical literature demonstrating that opioid tolerance is attenuated in chronic pain sufferers17,23,26. Indeed, clinical studies have repeatedly shown that morphine tolerance develops most robustly in those individuals consuming morphine in the absence of pain19,54. In the present study, male rats given CFA 24 hours before the 3-day morphine administration regimen showed significant increases in analgesia to all challenge doses of morphine, as
compared with non-injured animals. Several factors may contribute to the pain-induced attenuation in morphine tolerance. First, morphine, given in conjunction with peripheral inflammation, failed to illicit the increases in vlPAG microglia and astrocyte activity observed in non-CFA treated animals given morphine. Indeed, peripheral inflammatory pain blocked both morphine tolerance and morphine-induced glial cell activation within the vlPAG. As glia are not activated, no cytokine release would be expected, and, therefore, no net change in neuronal excitability. Alternatively, cannabinoids, which are released within the PAG during peripheral pain, have been shown to influence both glial activity and morphine analgesia. Cannabinoid receptor is robustly expressed within the vlPAG, with approximately 32% of cannabinoid receptor 1 (CB1) expressing neurons also expressing µ opioid receptor. Functionally, intra-PAG administration of a CB1 agonist enhances morphine analgesia, and systemic administration of cannabinoids, along with morphine, leads to the attenuation of morphine tolerance. Endocannabinoids also possess potent anti-inflammatory properties, which would likely block the activation of glia. Indeed, systemic administration of the cannabinoid receptor agonist WIN 55,212-2 prevents microglia and astrocyte activation, and decreases the release of the proinflammatory cytokines interleukin (IL)-1β, IL-6 and tumor necrosis factor (TNF)-α in the spinal cord.

In the present study, no glia activation was noted following administration of CFA alone. These results are in contrast with previous reports that peripheral pain, including CFA, peripheral neuropathy, formalin, and spinal nerve ligation induce significant glia activation within the spinal cord. However, given the roles of the spinal cord and PAG in pain facilitation and pain modulation, respectively, it is not entirely surprising that there
would be differential pain-induced regulation of glial activation in these two sites. Together, these studies suggest that inflammation elicits differential glial responses in a CNS region-dependent manner, and prevents morphine-induced increases in vIPAG glial cell activity.

How opioids activate glia

Opioid hyperalgesia is still observed in neuronal opioid receptor (mu, delta, and kappa) knockout mice\textsuperscript{36}, suggesting that the anti-analgesic affects of morphine (e.g., anti-analgesia and tolerance) are mediated by non-neuronal opioid receptors. Indeed, it was recently discovered that morphine analgesia is modulated not only by classical neuronal opioid receptors but also by non-classical glial receptor activity\textsuperscript{34}. Opioids have been shown to bind to Toll-like receptor 4 (TLR4)\textsuperscript{34}, an innate immune receptor located on microglia and astrocytes, and an abundance of evidence has accumulated indicating that TLR4 activity opposes morphine analgesia\textsuperscript{34, 86}. Functionally, animals that receive TLR4 antagonism, as well as TLR4 knockout mice, exhibit increased responsiveness to the analgesic properties of acute morphine administration\textsuperscript{86}. Similarly, systemic administration of TLR4 antagonists attenuates morphine tolerance\textsuperscript{34}. To date, the specific role of TLR4 in morphine tolerance development has not been elucidated. However, given our findings that the development of morphine tolerance correlates with increased vIPAG glial cell activation, and the evidence showing that TLR4 is expressed on rat PAG glia\textsuperscript{12, 40}, future studies investigating the potential role of vIPAG TLR4 in the development of morphine tolerance are warranted.

Conclusions

There is extensive literature supporting a critical role for glial cell activation in the development of morphine tolerance. Our findings that increased vIPAG glial activity is concurrent with the
development of morphine tolerance, and that pain inhibits both vlPAG glial reactivity and morphine tolerance development suggests that vlPAG glia play a significant role in the development of morphine tolerance. Taken together, our results may provide a direct neurobiological mechanism whereby chronic inflammatory pain attenuates the development of morphine tolerance, and implicate vlPAG glial cells as key regulators of this phenomenon.
ACKNOWLEDGEMENTS. National Institutes of Health grant DA16272 awarded to AZM supported this work. Morphine sulfate was kindly provided by the National Institute on Drug Abuse (NIDA) drug supply program.

DISCLOSURES. National Institutes of Health grant DA16272 awarded to AZM supported this work. Morphine sulfate was kindly provided by the National Institute on Drug Abuse (NIDA) drug supply program. The authors have no financial conflict of interest.


57. Ogoshi F, Yin HZ, Kuppumbatti Y, Song B, Amindari S, Weiss JH: Tumor necrosis-factor-alpha (tnf-alpha) induces rapid insertion of CA2+-permeable alpha-amino-3-hydroxyl-5-methyl-4-
isoxazole-propionate (AMPA)/kainate (Ca-a/k) channels in a subset of hippocampal pyramidal neurons. Exp Neurol 193:384-93, 2005.


**FIGURE LEGENDS**

**Figure 1.** Contralateral (A) and ipsilateral (B) PWL (in seconds) following intraplantar CFA or handling (Baseline), and after the first and third injection of morphine or saline in CFA+Morphine (n=6), CFA+Saline (n=7), Handled+Morphine (n=6), and Handled+Saline (n=5) treated male rats. The first and third injection of morphine caused an increase in contralateral and ipsilateral PWL as compared with saline controls (p<0.05; A & B, respectively). Contralateral PWL did not differ between CFA+Saline and Handled+Saline groups at any time point (p > 0.05; A). CFA treatment caused a significant decrease in ipsilateral PWL at all time points as compared with handled controls (p < 0.05; CFA+Saline; Handled+Saline; B). While uninjured animals treated with morphine showed a decrease in analgesia to the third injection as compared with the first (p < 0.05; A), CFA treated animals showed an increase in antihyperalgesia to the third injection (p < 0.05; B). Asterisks indicate significant differences between CFA+Morphine and Handled+Morphine groups.

**Figure 2.** PWL (in seconds) as a function of cumulative doses of morphine in handled (A & C), and CFA treated (B & D) male rats. Both ipsilateral (A & B) and contralateral (C & D) PWL data are presented. Animals received 3 consecutive days of morphine (5 mg/kg; sc, open circles) or saline (1 ml/kg; sc, filled circles). CFA+Morphine treated animals (n=7) did not differ from CFA+Saline treated animals (n=4) in response to cumulative morphine on day 5 (ipsilateral; F_{1,9}=1.128, p=0.3159 & contralateral; F_{1,5}=1.470, p=0.2563). Handled+Morphine treated animals (n=9) showed a significant decrease in PWL in response to cumulative morphine on day 5 as compared with Handled+Saline animals (n=5; ipsilateral; F_{1,12}=21.702, p=0.0006 & contralateral; F_{1,12}=20.373, p=0.0007).

**Figure 3.** Representative fluorescent photomicrographs of GFAP immunoreactivity in the vlPAG of animals treated with CFA+Morphine (a) and Handled+Morphine (b) (A). Densitometry of GFAP immunoreactivity in the vlPAG (B). Administration of morphine, in the absence of CFA (Handled+Morphine; n=7), resulted in a significant increase in GFAP immunoreactivity within the vlPAG (F_{3,22}=10.022, p=0.0002). No differences in GFAP levels were noted for the CFA+Morphine (n=11), CFA+Saline (n=4) or Handled+Saline control groups (n=4). Relative band intensity of GFAP/β-actin in the vlPAG (C). Administration of morphine, in the absence of CFA (Handled+Morphine; n=5), resulted in a significant increase in relative band intensity of GFAP/β-actin in the vlPAG (F_{3,19}=10.256, p=0.0003). No differences in GFAP levels were noted for the CFA+Morphine (n=5), CFA+Saline (n=7) or Handled+Saline (n=6) control groups.

**Figure 4.** Representative fluorescent photomicrographs of OX-42 immunoreactivity in the vlPAG of animals treated with CFA+Morphine (a) and Handled+Morphine (b) (A). Densitometry of OX-42 immunoreactivity in the vlPAG (B). Administration of morphine, in the absence of CFA (Handled+Morphine; n=8), significantly increased OX-42 immunoreactivity within the vlPAG (F_{3,19}=9.270, p=0.0005). No differences in OX-42 levels were noted for the CFA+Morphine (n=7), CFA+Saline (n=4) or Handled+Saline (n=4) control groups. Relative band intensity of OX-42/β-actin in the vlPAG (C). Administration of morphine, in the absence of CFA (Handled+Morphine;
n=5), resulted in an increase in relative band intensity of OX-42/β-actin in the vPAG (F3,10=2.544, p=0.1151); however, it did not reach significance.

**Figure 5.** Densitometry of GFAP (A) and OX-42 (B) immunoreactivity in the vPAG in Handled+Morphine (n=3), CFA+Morphine (n=4), Handled+Saline (n=4), and CFA+Saline (n=5) animals 24 hours following one morphine or saline injection. Neither CFA nor morphine (5 mg/kg, sc) increased vPAG GFAP (F3,12=0.494; p=0.693) or OX-42 (F3,12=0.162; p=0.9198) levels in the vPAG as compared to handled and saline controls.